Topic

Articles

Moving beyond the pill to extend the value being delivered to patients.

Changing the Digital Health Playing Field: A New Era

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.

“In Rare Diseases, It’s Personal”: Dr. Matthias Schmidt, JCR USA

Dr. Wolfram Lux is a Senior Director in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division.

Dr. Simone Seiter is a Partner at Simon-Kucher and is based in Frankfurt where she works for the global Pharma & Biotech practice within the Life Sciences division.

Christian M. Hinneburg is Consultant in Life Sciences at Simon-Kucher & Partners.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Adoption of Digital Technologies in Clinical Trials

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.

Refining, Rethinking, and Decentralizing Clinical Research

Jill Wechsler is Pharm Exec's Washington Corespondent

R&D on medical treatments lags notable success with vaccines.

Where Are the Therapeutics to Combat COVID-19?

Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.

Diversity in Clinical Trials Gains Ground during Pandemic

Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.

Accelerating Rare Disease Drug Development with NLP: Three Use Cases

Laura Child is CRO Sector Lead at ramarketing

Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.

New Horizons for Patient-Centric Drug Delivery

Hannah Brown & Elizabeth Baynton, Ipsos Global Autoimmune Therapy Monitors.

Hannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.

Challenges of Patient Engagement in Atopic Dermatitis

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

With pharma increasingly exploring the therapeutic potential of psychedelic drugs, Pharm Exec looks at how three companies in this space are developing their pipelines.








Tuning (Back) into Psychedelics

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Michael Henderson, Chief Business Officer, BridgeBio spoke to Pharm Exec about his efforts in developing potential treatments for rare diseases.

Looking to Past Research for the Development of New Drugs

Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments. 

 Tapping Microbiome Science for New Treatments and Answers to Drug Efficacy

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.

Advancing the Science for Minds: Dr. Husseini Manji, J&J

This week's much-anticipated meeting of FDA’s vaccine advisory committee will address critical issues related to the testing and approval of vaccines to prevent COVID-19 infection.

Early Vaccine Authorization Raises Ethical & Logistical Challenges for Trial Sponsors

Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.

Moving Toward the Pharmaceutical Industry of the Future with Translational Medicine

With all eyes on efforts to research and test potential vaccines and therapies to combat the coronavirus pandemic, fears about overly accelerated development programs has heightened demands for wider access to information on study protocols, statistical analysis plans, and early results.

COVID-19 Vaccine Concerns Prompt Clinical Trial Transparency

Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.

The Impact of Accelerated Drug Development

EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.

Expanding Access to CAR-T: Dr. Greg Frost

Dr. Volkmar Weckesser is Chief Information Officer, CENOTGENE GMBH

When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.

R&D/Clinical Trials